These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26632076)

  • 1. Donor Lymphocyte Infusion in Hematologic Malignancies--Good to be Fresh?
    Hossain NM; Klumpp T; Ulicny J; Garner M; Kropf PL; Mangan KF; Barta SK; Fung HC; Martin ME
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):111-5. PubMed ID: 26632076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
    Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
    JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
    Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prophylactic G-CSF mobilized donor lymphocytes infusion after non-myeloablative stem cell transplantation prevents relapse in patients with high-risk leukemia].
    Zhao HX; Sun WJ; Li J; Qiao JX; Huang YJ; Hu HL; Ai HS
    Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):922-5. PubMed ID: 24294845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
    J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor lymphocyte infusion for prophylaxis and treatment of relapse in pediatric hematologic malignancies after allogeneic hematopoietic stem cell transplant.
    Hou MH; Lee CY; Ho CY; Yu TY; Hung GY; Huang FL; Chiou TJ; Liu CY; Yen HJ
    J Chin Med Assoc; 2023 Nov; 86(11):991-1000. PubMed ID: 37697465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia.
    Liberio N; Robinson H; Nugent M; Simpson P; Margolis DA; Malarkannan S; Keever-Taylor C; Thakar MS
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27950. PubMed ID: 31368194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
    Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation.
    Warlick ED; DeFor T; Blazar BR; Burns L; Verneris MR; Ustun C; Weisdorf DJ; Miller JS
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):480-6. PubMed ID: 22155141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
    Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
    Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant.
    Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
    Bone Marrow Transplant; 2004 Jan; 33(2):231-6. PubMed ID: 14647258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
    Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
    Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; Tanaka J; Atsuta Y; Kanamori H
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1785-90. PubMed ID: 25034960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Salvage Chemotherapy Before Donor Lymphocyte Infusion in Patients With Relapse After Allogeneic Hematologic Stem Cell Transplantation.
    Aladag E; Goker H; Buyukasik Y; Demiroglu H
    Transplant Proc; 2021; 53(1):391-395. PubMed ID: 32665087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.
    Sairafi D; Remberger M; Uhlin M; Ljungman P; Ringdén O; Mattsson J
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1728-37. PubMed ID: 20542125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors.
    Liberatore C; Stanghellini MTL; Lorentino F; Vago L; Carrabba MG; Greco R; Marktel S; Assanelli A; Farina F; Corti C; Bernardi M; Peccatori J; Sockel K; Middeke JM; Schetelig J; Bergmann A; Rautenberg C; Ciceri F; Bornhäuser M; Schroeder T; Stölzel F
    Ther Adv Hematol; 2022; 13():20406207221090882. PubMed ID: 35747461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
    Lu N; Lin J; Wang LL; Li YY; Wang LJ; Gao CJ; Liu DH; Gao XN
    Int J Hematol; 2022 May; 115(5):713-727. PubMed ID: 35128587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.